Surging sales of vaccines and the cancer immunotherapy drug Keytruda led to a quadrupling of profit at Merck during the first quarter as it blew past Wall Street expectations. Sales of Keytruda jump 55% to $2.27 billion, about one-quarter of its total revenue. During the quarter, the injected biologic drug racked up U.S. approvals as […]